Nello Mainolfi - 03 Nov 2023 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Executive Officer, Director
Signature: /s/ Bruce N. Jacobs, as Attorney-in-Fact
Issuer symbol: KYMR
Transactions as of: 03 Nov 2023
Net transactions value: +$41,600
Form type: 4
Filing time: 06 Nov 2023, 18:00:05 UTC
Previous filing: 08 Aug 2023
Next filing: 02 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Options Exercise	$4,925	+2,368	+0.4%	$2.08^*	588,938	03 Nov 2023	Direct
transaction	KYMR	Common Stock	Options Exercise	$36,675	+17,632	+3%	$2.08^*	606,570	03 Nov 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Options Exercise	$0	-2,368	-100%	$0.000000^*	0	03 Nov 2023	Common Stock	2,368	$2.08	Direct	F1
transaction	KYMR	Stock Option (Right to Buy)	Options Exercise	$0	-17,632	-3.2%	$0.000000	528,972	03 Nov 2023	Common Stock	17,632	$2.08	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.
F2	The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date.